Drug Profile


Alternative Names: K 12148

Latest Information Update: 02 Oct 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Klinge Pharma
  • Developer Klinge Pharma; Merckle
  • Class Antihyperlipidaemics; Benzamides; Small molecules
  • Mechanism of Action Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 02 Oct 1997 Discontinued-II for Hypercholesterolaemia in Germany (PO)
  • 30 Mar 1995 Two studies in patients with primary hypercholesterolaemia have been added to the therapeutic trials section ,
  • 16 Dec 1994 A study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top